Joshua Derryberry, MD
Family Medicine · Chattanooga, TNNPI 1396980009
Payments from drug & device makers
Across 187 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- AbbVie$208
- Abbott$111
- GSK$109
- Pfizer$50
- Lilly USA, LLC$48
- plus $393 from 16 others
What the payments were for
- Food & beverage$3,506100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 131 | $2,599 |
| AbbVie | 19 | $208 |
| Abbott | 6 | $111 |
| GSK | 6 | $109 |
| Pfizer | 3 | $50 |
| Lilly USA, LLC | 3 | $48 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Seqirus USA Inc | 2 | $36 |
| AstraZeneca | 2 | $33 |
| Medtronic | 1 | $31 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Neurelis, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Optinose US, Inc. | 1 | $24 |
| Antares Pharma, Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Amgen | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
How this compares
$3,518 in reported general payments places this provider in the 75th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 134 | $225,472 |
| EliquisApixaban | 115 | $113,570 |
| TrulicityDulaglutide | 40 | $62,961 |
| MounjaroTirzepatide | 21 | $27,996 |
| JardianceEmpagliflozin | 17 | $20,446 |
| XareltoRivaroxaban | 21 | $19,761 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $16,553 |
| Emgality PenGalcanezumab-Gnlm | 23 | $16,081 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $14,719 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $14,561 |
| NucyntaTapentadol Hcl | 11 | $6,535 |
| Atorvastatin Calcium | 429 | $5,388 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $4,916 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $4,580 |
| Fluticasone Propionate | 251 | $4,456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,599 | $225,472134 claims |
| PfizerEliquis | $50 | $113,570115 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $48 | $90,95761 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $109 | $31,11436 claims |
| Boehringer IngelheimJardiance | $17 | $20,44617 claims |
| AbbVieSynthroid | $208 | $2,86439 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Chattanooga
- Natasha BallardChattanooga$5.7M
- Ellen ClelandChattanooga$38K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.